Shandong Buchang Pharmaceuticals Co Ltd (SHG:603858) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Buchang Pharmaceuticals Co Ltd (603858)
Shandong Buchang Pharmaceuticals Co Ltd (SHG:603858) has a market capitalization of $2.38 Billion (CN¥16.27 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #5594 globally and #1030 in its home market, demonstrating a -1.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Buchang Pharmaceuticals Co Ltd's stock price CN¥15.43 by its total outstanding shares 1054568442 (1.05 Billion). See Shandong Buchang Pharmaceuticals Co Ltd capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Shandong Buchang Pharmaceuticals Co Ltd Market Cap History: 2016 to 2026
Shandong Buchang Pharmaceuticals Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $6.40 Billion to $2.38 Billion (-8.09% CAGR).
Shandong Buchang Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Buchang Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Shandong Buchang Pharmaceuticals Co Ltd's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.40 Billion | $12.32 Billion | $1.77 Billion | 0.52x | 3.62x |
| 2017 | $3.50 Billion | $13.86 Billion | $1.64 Billion | 0.25x | 2.14x |
| 2018 | $2.39 Billion | $13.66 Billion | $1.89 Billion | 0.17x | 1.26x |
| 2019 | $2.74 Billion | $14.26 Billion | $1.95 Billion | 0.19x | 1.41x |
| 2020 | $3.24 Billion | $16.01 Billion | $1.86 Billion | 0.20x | 1.74x |
| 2021 | $3.04 Billion | $15.76 Billion | $1.29 Billion | 0.19x | 2.36x |
| 2022 | $3.08 Billion | $14.95 Billion | -$1.53 Billion | 0.21x | N/A |
| 2023 | $2.62 Billion | $13.25 Billion | $318.97 Million | 0.20x | 8.23x |
| 2024 | $2.44 Billion | $11.01 Billion | -$553.80 Million | 0.22x | N/A |
Competitor Companies of 603858 by Market Capitalization
Companies near Shandong Buchang Pharmaceuticals Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Shandong Buchang Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #556 globally with a market cap of $48.64 Billion USD ( CN¥332.41 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.91 |
| #556 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.64 Billion | CN¥52.11 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Shandong Buchang Pharmaceuticals Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Shandong Buchang Pharmaceuticals Co Ltd's market cap moved from $6.40 Billion to $ 2.38 Billion, with a yearly change of -8.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.38 Billion | -1.34% |
| 2025 | CN¥2.41 Billion | -1.01% |
| 2024 | CN¥2.44 Billion | -7.11% |
| 2023 | CN¥2.62 Billion | -14.91% |
| 2022 | CN¥3.08 Billion | +1.58% |
| 2021 | CN¥3.04 Billion | -6.13% |
| 2020 | CN¥3.24 Billion | +17.92% |
| 2019 | CN¥2.74 Billion | +14.95% |
| 2018 | CN¥2.39 Billion | -31.76% |
| 2017 | CN¥3.50 Billion | -45.35% |
| 2016 | CN¥6.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Shandong Buchang Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.38 Billion USD |
| MoneyControl | $2.38 Billion USD |
| MarketWatch | $2.38 Billion USD |
| marketcap.company | $2.38 Billion USD |
| Reuters | $2.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.